Wall Street expects Nurix Therapeutics to report a Q3 2026 loss of $0.60 per share on revenue of $24.35 million, as the stock currently trades near $22.88 against a $33.93 average price target.
Investors are primarily focused on clinical updates for lead candidate NX-5948, specifically its performance in the pivotal Phase 2 DAYBreak CLL-201 trial for B-cell malignancies. Recent performance has been driven by optimism surrounding the company's targeted protein degradation platform and its expanding collaborations with partners like Sanofi and Gilead.
Market participants are also monitoring the company's cash runway and R&D efficiency following several consecutive quarters of revenue misses and capital-intensive clinical development.